Literature DB >> 26698265

Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome.

F P Busardò1, C Kyriakou, S Napoletano, E Marinelli, S Zaami.   

Abstract

Gamma-hydroxybutyrate (GHB) is a short chain fatty acid endogenously produced within the central nervous system (CNS) and acts as a precursor and metabolite of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Although, it is an illegal recreational drug of abuse, its sodium salt (sodium oxybate) has been utilized as a medication for a number of medical conditions. The first aim of this review was to focus on current applications of sodium oxybate for the treatment of narcolepsy, with a particular emphasis on the key symptoms of this disorder: cataplexy and excessive daytime sleepiness (EDS). Secondly, the effectiveness of sodium oxybate therapy for the treatment of alcohol withdrawal syndrome (AWS) and the maintenance of alcohol abstinence has been assessed. Nowadays, sodium oxybate is the first-line treatment for narcolepsy and it is highly effective in meliorating sleep architecture, decreasing EDS and the frequency of cataplexy attacks in narcoleptic patients. Sodium oxybate currently finds also application in the treatment of AWS and the maintenance of alcohol abstinence in alcoholics. Most of the studies evaluating the efficacy of GHB in the treatment of AWS use a dosage of 50 mg/kg divided in three or four administrations per day. Human studies showed that GHB (dose of 50 mg/kg, divided in three administrations per day) is capable to increase the number of abstinent days, reduce alcohol craving and decrease the number of drinks per day. However, there is limited randomized evidence and, thus, GHB cannot be reliably compared to clomethiazole or benzodiazepines. Some randomized data suggest that GHB is better than naltrexone and disulfiram regarding abstinence maintenance and prevention of craving in the medium term i.e. 3-12 months. It is recommended that GHB should be used only under strict medical supervision, since concerns about the abuse/misuse of the drug and the addiction potential have been arisen.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26698265

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  12 in total

Review 1.  Pitolisant: A Review in Narcolepsy with or without Cataplexy.

Authors:  Yvette N Lamb
Journal:  CNS Drugs       Date:  2020-02       Impact factor: 5.749

2.  Sodium Oxybate for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson Disease: A Randomized Clinical Trial.

Authors:  Fabian Büchele; Marc Hackius; Sebastian R Schreglmann; Wolfgang Omlor; Esther Werth; Angelina Maric; Lukas L Imbach; Stefan Hägele-Link; Daniel Waldvogel; Christian R Baumann
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

3.  Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods.

Authors:  Jana Janockova; Rafael Dolezal; Eugenie Nepovimova; Tereza Kobrlova; Marketa Benkova; Kamil Kuca; Jan Konecny; Eva Mezeiova; Michaela Melikova; Vendula Hepnarova; Avi Ring; Ondrej Soukup; Jan Korabecny
Journal:  Molecules       Date:  2018-11-09       Impact factor: 4.411

Review 4.  Alcohol withdrawal syndrome: mechanisms, manifestations, and management.

Authors:  S Jesse; G Bråthen; M Ferrara; M Keindl; E Ben-Menachem; R Tanasescu; E Brodtkorb; M Hillbom; M A Leone; A C Ludolph
Journal:  Acta Neurol Scand       Date:  2016-09-01       Impact factor: 3.209

Review 5.  Gamma-hydroxybutyrate abuse: pharmacology and poisoning and withdrawal management.

Authors:  Enrico Marinelli; Renata Beck; Antonio Malvasi; Alfredo Fabrizio Lo Faro; Simona Zaami
Journal:  Arh Hig Rada Toksikol       Date:  2020-03-01       Impact factor: 1.948

Review 6.  Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.

Authors:  Elizabeth M Burnette; Steven J Nieto; Erica N Grodin; Lindsay R Meredith; Brian Hurley; Karen Miotto; Artha J Gillis; Lara A Ray
Journal:  Drugs       Date:  2022-02-08       Impact factor: 9.546

Review 7.  Baclofen in gamma-hydroxybutyrate withdrawal: patterns of use and online availability.

Authors:  Christopher N Floyd; David M Wood; Paul I Dargan
Journal:  Eur J Clin Pharmacol       Date:  2017-12-03       Impact factor: 2.953

8.  Analysis of Factors Associated with Hiccups Using the FAERS Database.

Authors:  Ryuichiro Hosoya; Reiko Ishii-Nozawa; Kota Kurosaki; Yoshihiro Uesawa
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-24

9.  Has GBL replaced GHB in recreational settings?

Authors:  Anastasio Tini; Alessandro Del Rio
Journal:  Arh Hig Rada Toksikol       Date:  2020-06-29       Impact factor: 2.078

10.  GHB analogs confer neuroprotection through specific interaction with the CaMKIIα hub domain.

Authors:  Ulrike Leurs; Anders B Klein; Ethan D McSpadden; Nane Griem-Krey; Sara M Ø Solbak; Josh Houlton; Inge S Villumsen; Stine B Vogensen; Louise Hamborg; Stine J Gauger; Line B Palmelund; Anne Sofie G Larsen; Mohamed A Shehata; Christian D Kelstrup; Jesper V Olsen; Anders Bach; Robert O Burnie; D Steven Kerr; Emma K Gowing; Selina M W Teurlings; Chris C Chi; Christine L Gee; Bente Frølund; Birgitte R Kornum; Geeske M van Woerden; Rasmus P Clausen; John Kuriyan; Andrew N Clarkson; Petrine Wellendorph
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.